about
sameAs
Optimization of the bacterial cytochrome P450 BM3 system for the production of human drug metabolitesComparison of the refined crystal structures of wild-type (1.34 A) flavodoxin from Desulfovibrio vulgaris and the S35C mutant (1.44 A) at 100 KRedox properties and crystal structures of a Desulfovibrio vulgaris flavodoxin mutant in the monomeric and homodimeric formsStructural Basis for the Functional Roles of Critical Residues in Human Cytochrome P450 AromataseSubtle structural changes in the Asp251Gly/Gln307His P450 BM3 mutant responsible for new activity toward diclofenac, tolbutamide and ibuprofenEngineering and design in the bioelectrochemistry of metalloproteins.Resolution of the heterogeneous fluorescence in multi-tryptophan proteins: ascorbate oxidase.Identification of mutant Asp251Gly/Gln307His of cytochrome P450 BM3 for the generation of metabolites of diclofenac, ibuprofen and tolbutamide.Human flavin-containing monooxygenase 3 on graphene oxide for drug metabolism screening.Site saturation mutagenesis demonstrates a central role for cysteine 298 as proton donor to the catalytic site in CaHydA [FeFe]-hydrogenase.Hydroxylation of non-substituted polycyclic aromatic hydrocarbons by cytochrome P450 BM3 engineered by directed evolution.Evidence for an elevated aspartate pK(a) in the active site of human aromataseDynamics and flexibility of human aromatase probed by FTIR and time resolved fluorescence spectroscopyLaser-written nanoporous silicon diffraction gratings for biosensors.Improvement of biocatalysts for industrial and environmental purposes by saturation mutagenesisDirected evolution of enzymes for product chemistry.Identification of endocrine disrupting chemicals acting on human aromatase.Breakthrough in P450 bioelectrochemistry and future perspectives.Human aromatase: perspectives in biochemistry and biotechnology.Chimeric P450 enzymes: activity of artificial redox fusions driven by different reductases for biotechnological applications.Modulation of the interaction between human P450 3A4 and B. megaterium reductase via engineered loops.Impact of R264C and R264H polymorphisms in human aromatase function.Human Cytochrome P450 3A4 as a Biocatalyst: Effects of the Engineered Linker in Modulation of Coupling Efficiency in 3A4-BMR Chimeras.Human flavin-containing monooxygenase 3: Structural mapping of gene polymorphisms and insights into molecular basis of drug binding.Atypical effect of temperature tuning on the insertion of the catalytic iron-sulfur center in a recombinant [FeFe]-hydrogenase.Escherichia coli Overexpressing a Baeyer-Villiger Monooxygenase from Acinetobacter radioresistens Becomes Resistant to Imipenem.Electrochemistry of Canis familiaris cytochrome P450 2D15 with gold nanoparticles: An alternative to animal testing in drug discovery.Engineering type 1 copper sites in proteins.A rapid screening for cytochrome P450 catalysis on new chemical entities: cytochrome P450 BM3 and 1,2,5-oxadiazole derivatives.An electrochemical microfluidic platform for human P450 drug metabolism profiling.Control of human cytochrome P450 2E1 electrocatalytic response as a result of unique orientation on gold electrodes.Direct electrochemistry of drug metabolizing human flavin-containing monooxygenase: electrochemical turnover of benzydamine and tamoxifen.Catalytic properties of catechol 1,2-dioxygenase from Acinetobacter radioresistens S13 immobilized on nanosponges.Biohydrogen and biomethane production sustained by untreated matrices and alternative application of compost waste.Characterisation of the electron transfer and complex formation between flavodoxin from D. vulgaris and the haem domain of cytochrome P450 BM3 from B. megaterium.Tuning the reduction potential of engineered cytochrome c-553.Entrapment of human flavin-containing monooxygenase 3 in the presence of gold nanoparticles: TEM, FTIR and electrocatalysis.The oxygenase component of phenol hydroxylase from Acinetobacter radioresistens S13.Direct electrochemistry of immobilized human cytochrome P450 2E1.Engineering Macaca fascicularis cytochrome P450 2C20 to reduce animal testing for new drugs.
P50
Q27027286-E31D7C7E-038D-40E3-80C0-FF21F8E80A46Q27639707-0A18A106-5015-4E1B-ABD7-0EC34CA0AC8AQ27653313-2E2AD9F4-E6AA-4A81-9987-E2C71580FF82Q27679279-7418BF75-F67C-4777-AF83-9B443B496E2DQ27703276-43E1F627-87D8-4361-9740-9C3DCBCDA94EQ30328525-3411FE41-0B0E-4B5C-9ECD-0A2AB3B24917Q30432020-285C2955-3CD9-452D-86A9-283C01239EE4Q34159860-DA937905-E50F-41B7-A248-E0E028E129A6Q34460195-1372E470-D8CC-4369-9A2D-9FAACD2644F2Q34469478-5B9AC57E-A747-45F1-A805-D5993203F654Q34520962-70F70B7D-29C7-4724-BC2E-C2BD01C2EE3CQ34958506-46CC9B73-D21C-4B6E-945D-B4F7C0773D6EQ35069990-CCA805C8-4C07-45D7-90D6-677AD7D42667Q35090227-11EEA932-ADEA-4F5F-BD04-FD04B245F55BQ35196065-34716B34-0078-418F-931C-5D283D074919Q35849944-5122E627-3926-436A-BA3B-7F3DAAC05E50Q36391873-EE1E3ED4-709B-45F0-87F2-64A4FC509F49Q37774471-0A73FD6F-6AE5-484B-8F00-8D0029DE4676Q38099058-3A567B57-ABA2-4B55-938A-75E8ED4E203BQ38099059-A9F06B6D-08FB-4618-A9DB-E42F3162472FQ38666487-365ED7A3-72D5-41DF-BDD8-72D6E1B5325CQ38742512-8D37A6FC-B024-4EE3-9B4B-036F16CF1AC8Q38854435-D173582E-0D5A-4BD3-B171-BD331FF07430Q39491475-7060B465-9163-478A-B7A7-31EEBDA376CFQ39719477-B9635F3A-9FF4-4508-AA08-00E17679F683Q40439693-6F26D9ED-22BC-45FD-BD94-9C5317A5FC80Q40818495-4048FAEA-921C-4413-B523-4993662DE85EQ40918569-DCF3C66A-41D5-47E5-8DA7-5F343962F2AAQ42668307-FF935FA3-6459-4515-BD3C-828B9F14EAC5Q42792930-18616B2F-0858-4C94-BD23-144D33E82189Q43052789-8A5E6E62-461F-41F1-AB9A-0C0EFC54A670Q43211786-525FAD89-7F1C-4C93-B937-E167BC723FAFQ43293637-D3F733FC-EE79-4710-A091-FE9CA7B3BE38Q43351916-F575ED20-A52E-486D-88F6-F1483E8581BBQ43868909-00828FDB-BF1E-4FA2-97A4-97D90A330FEAQ44047124-0B214314-7A7B-4423-BC24-FDD83EAB0649Q44399354-E0DBDBEC-8B5C-4219-85CD-EB39D47909BCQ44444497-3AE46615-EEFE-4805-845A-714532BDA666Q44852355-59D8DC34-E89A-4588-BD1B-5DA69E2ECAF8Q45165333-68568D72-F292-4950-899D-D3D87E1DE95D
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gianfranco Gilardi
@ast
Gianfranco Gilardi
@en
Gianfranco Gilardi
@es
Gianfranco Gilardi
@nl
Gianfranco Gilardi
@sl
type
label
Gianfranco Gilardi
@ast
Gianfranco Gilardi
@en
Gianfranco Gilardi
@es
Gianfranco Gilardi
@nl
Gianfranco Gilardi
@sl
altLabel
Franco Gilardi
@en
prefLabel
Gianfranco Gilardi
@ast
Gianfranco Gilardi
@en
Gianfranco Gilardi
@es
Gianfranco Gilardi
@nl
Gianfranco Gilardi
@sl
P1053
B-4523-2010
P106
P1153
7005806856
P21
P2798
P31
P3829
P496
0000-0002-6559-276X